Home › Research › Prevention and risk
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis
Celia Louise Gregson, David Armstrong, Christina Avgerinou, Jean Bowden, Cyrus Cooper, Lucy Douglas, John Edwards, Neil J. L. Gittoes et al.. Archives of Osteoporosis, 2025-09-08
Topic: Risk, prevention and care in population studies
Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, as well as models of care for fracture prevention. Recommendations are made for training, service leads and commissioners of healthcare, and for review criteria for audit and quality improvement. Specific 2024 updates include guidance on fracture risk assessment by ethnicity, Parkinson's disease, Down's syndrome and lower-limb amputation; furthermore, the definition of very high fracture risk has been clarified. Hormone replacement therapy (HRT) is now recommended as a first-line treatment option in younger postmenopausal women with high fracture risk and low baseline risk for adverse events; recommendations regarding abaloparatide are included; additional training resources have been added. The guideline provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
Key findings
- Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, as well as models of care for fracture prevention.
- Recommendations are made for training, service leads and commissioners of healthcare, and for review criteria for audit and quality improvement.
- Specific 2024 updates include guidance on fracture risk assessment by ethnicity, Parkinson's disease, Down's syndrome and lower-limb amputation; furthermore, the definition of very high fracture risk has been clarified.
- Hormone replacement therapy (HRT) is now recommended as a first-line treatment option in younger postmenopausal women with high fracture risk and low baseline risk for adverse events; recommendations regarding abaloparatide are included; additional training resources have been added.
- The guideline provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management.
Why it matters
This guideline is about the prevention and treatment of osteoporosis, not about Alzheimer's disease. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designmeta-analysis
- Evidence strengthHigh
How this study scored 67/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 64 of the 96 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of Osteoporosis) |
| Journal's citation record | 0 / 4 | Archives of Osteoporosis: journal h-index 66 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | A review of other studies — randomisation is not credited here |
| Times cited | 4 / 7 | Cited 99 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 33.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 6 / 6 | Cited 93.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 99 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of Oxford: institution h-index 2,205 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 25 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40921943) |
| Free to read | 2 / 2 | Free to read |
| Points | 64 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 64 of the 96 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s11657-025-01588-3
- PubMed: 40921943
- Original source →
- Free full text: Archives of Osteoporosis →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Gregson, C. L., Armstrong, D., Avgerinou, C., Bowden, J., Cooper, C., Douglas, L., et al. (2025). The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis. https://doi.org/10.1007/s11657-025-01588-3
Vancouver
Gregson CL, Armstrong D, Avgerinou C, Bowden J, Cooper C, Douglas L, et al. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis. 2025. doi:10.1007/s11657-025-01588-3. PMID: 40921943.
BibTeX
@article{gregson2025-40921943,
author = {Gregson, Celia Louise and Armstrong, David and Avgerinou, Christina and Bowden, Jean and Cooper, Cyrus and Douglas, Lucy and Edwards, John and Gittoes, Neil J. L. and others},
title = {{The 2024 UK clinical guideline for the prevention and treatment of osteoporosis}},
journal = {Archives of Osteoporosis},
year = {2025},
doi = {10.1007/s11657-025-01588-3},
pmid = {40921943},
url = {https://doi.org/10.1007/s11657-025-01588-3}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Prevention and risk
Also in Prevention and risk
265 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.